Abstract:Introduction: Acute renal failure secondary to ischemia/reperfusion (I/R) injury poses a significant burden on both surgeons and patients. It carries a high morbidity and mortality rate and no specific treatment currently exists. Significant causes of renal I/R injury include trauma, sepsis, hypoperfusion, and various surgical procedures. Adrenomedullin (AM) is a novel vasoactive peptide and adrenomedullin binding protein-1 (AMBP-1) is a specific AM binding protein which augments the activity of AM. We have demonstrated that AM combined with AMBP-1 is beneficial in various disease conditions. However, it remains unknown whether human AM/AMBP-1 provides any beneficial effects in renal I/R injury. Objective: To determine if administration of human AM/AMBP-1 can prevent and/or minimize damage in a rat model of renal I/R injury. Methods: Male adult rats were subjected to bilateral renal pedicle clamping with microvascular clips for 60 min. Administration of either vehicle (normal saline) or human AM (12 μg/kg) and AMBP-1 (40 μg/kg) was given intravenously over 30 min immediately following clip removal (i.e., reperfusion). Rats were allowed to recover for 24 h post treatment, and then sacrificed for sampling. Blood was collected and measured for systemic markers of tissue injury and inflammation. Renal samples were harvested for water content and TNF-α analysis. Results: Systemic markers of tissue injury were significantly increased following renal I/R and infusion of normal saline. As shown in the table below, plasma creatinine and BUN levels were markedly elevated as compared to sham animals. Renal water content was also significantly increased. Furthermore, liver injury markers AST and ALT, as well as TNF-α levels, were elevated after renal I/R. Administration of human AM/AMBP-1 decreased plasma levels of creatinine by 64% following renal I/R as compared to vehicle infused animals, and serum levels of BUN decreased by 47% in the treatment group. Human AM/AMBP-1 significantly decreased the renal water content, and plasma levels of AST and ALT showed a 26% and a 32% reduction, respectively, following treatment. Furthermore, treatment with human AM/AMBP-1 reduced the pro-inflammatory cytokine TNF-α by 20% in the serum. Renal tissue TNF-α levels (pg/mg protein) were reduced by 23% (2035±175 in AM/AMBP-1 vs. 2653±245 in vehicle; p<0.05, n=6; Sham=667±125). A Western blot analysis of serum AMBP-1 was conducted and resulted in a significant decrease in animals post renal I/R injury, down from 4.6±0.5 to 2.1±0.6 (arbitrary unit; p<0.05, n=4), suggesting that the decreased AMBP-1 levels may play an important role in renal I/R injury. Conclusion: Administration of human AM/AMBP-1 significantly decreased systemic markers of tissue injury and inflammation after renal I/R. Therefore, human AM combined with AMBP-1 may be developed as a novel treatment in patients following renal I/R injury.

Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis

Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model

Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects

Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis

Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats

Effect of HSP70 Gene Transfection to Rat Peripheral Blood Cytokines in the Early Phase of Sepsis

Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis

Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines

Human Adrenomedullin and Its Binding Protein Ameliorate Sepsis-Induced Organ Injury and Mortality in Jaundiced Rats

Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage

Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)

Adrenomedullin in heart failure: pathophysiology and therapeutic application

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis

Alpha1-antitrypsin improves survival in murine abdominal sepsis model by decreasing inflammation and sequestration of free heme

Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock

Human AM/AMBP-1 Attenuates Renal Ischemia/Reperfusion Injury in the Rat

Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial

Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion

Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma

Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation